Misplaced Pages

Molecular tumor board

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (July 2024)
Globe icon.The examples and perspective in this article deal primarily with the United States and do not represent a worldwide view of the subject. You may improve this article, discuss the issue on the talk page, or create a new article, as appropriate. (October 2021) (Learn how and when to remove this message)
(Learn how and when to remove this message)

A Molecular Tumor Board (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity. It has also been called a Sequencing Tumor Board and it is characterized by the in-depth application of molecular analysis (e.g. genomics and transcriptomics) for a single patient. Molecular Tumor Boards are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas. The boards are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists. MTBs are considered to improve clinical outcomes for patients with tumors with unique molecular profiles.

Molecular Tumour Boards have been used by a number of institutions, like the Dartmouth–Hitchcock Medical Center, the Johns Hopkins Hospital and the Moffitt Cancer Center.

References

  1. ^ Luchini C, Lawlor RT, Milella M, Scarpa A (September 2020). "Molecular Tumor Boards in Clinical Practice". Trends in Cancer. 6 (9): 738–744. doi:10.1016/j.trecan.2020.05.008. PMID 32517959. S2CID 219561620.
  2. ^ Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. (November 2011). "Personalized oncology through integrative high-throughput sequencing: a pilot study". Science Translational Medicine. 3 (111): 111ra121. doi:10.1126/scitranslmed.3003161. PMC 3476478. PMID 22133722.
  3. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. (October 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications. 11 (1): 4965. Bibcode:2020NatCo..11.4965K. doi:10.1038/s41467-020-18613-3. PMC 7532150. PMID 33009371.
  4. Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, et al. (November 2017). "Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board". JCO Precision Oncology. 2017 (1): 1–19. doi:10.1200/po.16.00046. PMC 6039131. PMID 30003184.
  5. Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, et al. (February 2017). "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience". The Oncologist. 22 (2): 144–151. doi:10.1634/theoncologist.2016-0195. PMC 5330702. PMID 28179575.


Stub icon

This oncology article is a stub. You can help Misplaced Pages by expanding it.

Categories: